Summary
Improving the science of abuse assessment before a drug is marketed is a unified goal for the FDA and pharmaceutical industry. It is the hope that public health will be protected through placing appropriate controls, such as accurate labeling information and marketing practices, to reduce the likelihood that a drug will be abused after FDA approval.
Register to download
The Fundamentals of Human Abuse Potential (HAP) Studies: A 7-Point Checklist
You may also be interested in:
White Paper
Strategies for Accelerating Rare Disease Clinical Development
Rare disease trials differ from those in most other therapeutic areas because the indications are more complex and involve smaller patient…
Poster
Real-World Misuse Abuse and Dependence of Abuse Deterrent
Abuse deterrent formulations of opioid medications (ADOs) may help curtail the widespread abuse, misuse, and diversion of these products.With the…
White Paper
The Patient Voice: Engaging Rare Disease Patients Improves Clinical Trial Enrollment & Retention
Clinical trials in rare diseases are complex and present unique challenges. However, patients in these trials are very vocal, with caretakers, family…